Listen Live

INDIANAPOLIS--The U.S. government has placed a $1.29 billion order to Eli Lilly for another 614,000 doses of its COVID-19 drug cocktail of bamlinivab and etesevimab.

The administration at Eli Lilly says it will supply at least 400,000 doses of the cocktail, which is authorized for emergency use to treat mild to moderate COVID-19 symptoms in adults age 12 or older. It can also be used for post-exposure prevention of Covid-19 in certain individuals, by the end of the year, with the remainder delivered by the end of January 2022.

Lilly estimates the impact of the new purchase to the 2021 guidance is $840 million of additional revenue and approximately 25 cents of additional earnings per share. The expected impact in 2022 will be reflected in the company’s financial guidance to be provided in December 2021.

Lilly warns that there is limited clinical data available for bamlanivimab and etesevimab. Serious and unexpected adverse events “may occur that have not been previously reported with the use of bamlinivab and etesevimab together,” said Lilly in a press release Tuesday morning.

They also advise you to speak with your doctor before considering using the cocktail.